North Central Treatment Group Administrative Report Status of All Currently Open Protocols As of 02/04/2008 Table 1

Size: px

Start display at page:

Download "North Central Treatment Group Administrative Report Status of All Currently Open Protocols As of 02/04/2008 Table 1"

Marion Burns
5 years ago
Views:

1 Number Protocol Description Disease#Site=Breast =Treatment A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer (SOFT) A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer (TEXT) Cyclophosphamide and Doxorubicin (CA) (4 vs. 6 Cycles) Versus Paclitaxel (4 vs. 6 Cycles) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph Nodes: A 2x2 Factorial Phase III Randomized Study Endocrine Therapy With or Without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial for Postmenopausal Women with Estrogen-Receptor Positive Advanced Breast Cancer B-36 Adjuvant Therapy Comparing Six Cycles of 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) to Four Cycles of Adriamycin and Cyclophosphamide (AC) With or Without Celecoxib, in Patients with Node-Negative Breast Cancer B-39 NSABP B-39, ""A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I or II Breast Cancer"" E5103 MA.17 MA.27 N0337 N0537 N0539 NSABP-B-40 E5103, A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer A Phase III Randomized Double Blind Study of Letrozole Versus Placebo in Women With Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen A Randomized Phase III Trial of Exemestane Versus Anastrozole in Postmenopausal Women with Receptor Positive Primary Breast Cancer Phase II Study of Capecitabine in Combination with Vinorelbine and Trastuzumab for the First- or Second-Line Treatment of HER2+ Metastatic Breast Cancer Phase II Trial of VEGF Trap in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and/or Taxane Phase II Trial of Fulvestrant and Bevacizumab in Patients with Metastatic Breast Cancer Previously Treated with an Aromatase Inhibitor A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pcr) of Adding Capcitabine or Gemcitabine to docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pcr with Each of the Regimens

2 Number NSABP-B42 S0221 S0226 S0307 Protocol Description Disease#Site=Breast =Treatment A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopaulsal Women With Metastatic Breast Cancer Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer Z1031 CTSU Z1031, A Randomized Phase III Trial Comparing 16 to 18 Weeks of neoadjuvant Exemestane (25 mg daily) Letrozole or Anastrozole in Postmenoupausal Women with Clinical State II and II estrogen Recepto Positive Breast Cancer Disease#Site=Breast =Ancillary Quality of Life, Employment and Informal Care Cost Analysis in Women Receiving Adjuvant Chemotherapy for Node-Negative Breast Cancesr (Companion to CALGB 40101) M/N - Phase III Trial of Adjuvant Therapy with Tamoxifen Alone or Combined with Fluoxymesterone in Postmenopausal Women with Resected Estrogen Receptor Positive Breast Cancer - Buccal Cell Study - translational component 9313 Phase III Comparison of Adjuvant Chemotherapy With High-Dose Cyclophosphamide Plus Doxorubicin (AC) Versus Sequential Doxorubicin Followed by Cyclophosphamide (A-C) in High-Risk Breast Cancer Patients With 0-3 Postive Nodes - Translational Component MA.27B N0434 N0537 MA.27B, The Influence of Five Years of Adjuvant Anastrozole or Exemestane on Bone Mineral Density in Postmenopausal Women with Primry Breast Cancer, A Companion Study to NCIC MA.27 The Association of Breast Density Changes, Plasma Hormone Changes, and Breast Cancer Recurrence : A Companion Study To NCIC CTG MA.27 Phase II Trial of VEGF Trap in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and/or Taxane - Translational Component N0539 Progesterone receptor (PgR) expression by IHC N063I Changes in Breast Density and Plasma Hormone Levels After One Year of Aromatase Inhibitor Therapy - Translational Component

3 PACCT-1 S0307 Disease#Site=Breast =Ancillary Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial Phase III Study of Bisphosphonates as Adjuvant Therapy in Breast Cancer - Translational Component Site

4 Disease#Site=CNS =Treatment 0525 Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-Intensive Temozolomide in Patients with Newly Diagnosed Glioblastoma N0177 N0272 N027D N047B N0572 N0574 A Pilot and Phase II Study of OSI-774 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI-571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma A Phase I Study of CCI-779 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme A Phase II Trial of Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Recurrent Glioblastoma A Phase I/II Trial of Sorafenib and CCI-779 in Patients with Recurrent Glioblastoma A Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to Radiosurgery in the Management of Patients with One to Three Cerebral Metastases - pre registration Disease#Site=CNS =Ancillary 0525 Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-Intensive Temozolomide in Patients with Newly Diagnosed Glioblastoma - Translational Component Diagnostic and Prognostic Markers in High-Grade Glioma Diagnostic and Prognostic Markers in Low-Grade Glioma Clinical Significance of Histologic Typing of High-Grade Glioma N0177 N0272 N027D A Pilot and Phase II Study of OSI-774 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme - Translational Component Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI-571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma - Translational Component A Phase I Study of CCI-779, Temozolomide and Radiation in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) - Translational Component N0477 Optimizing EGFR Inhibitor-Based Therapies for GBM N047B N0572 A Phase II Trial of Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Recurrent Glioblastoma - Translational Component Phase I/II Study of Sorafenib and CCI-779 in Patients with Recurrent Glioblastoma - Translational Component

5 Disease#Site=CNS =Ancillary Site

6 Disease#Site=GI =Treatment 5202 A Randomized Phase III Study Comparing 5-FU, Leucovorin, and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin, and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma E5204 N0147 N0543 Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer - Pre-registration A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma R-04 A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with or without Oxaliplatin with Preoperative Radiation Therapy and Continuous Intravenous Infusion of 5-Fluorouracil with or without Oxaliplatin in the Treatment of Patients with Operable Carcinoma of the Rectum S0600 Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC ) with or without Bevacizumab (NSC ) as Second-Line Therapy for Patients With Metastatic Colorectal Cancer who Have Progressed on Bevacizumab with either FOLFOX, OPTIMOX, or XELOX Disease#Site=GI =Ancillary Chemotherapy and Biological Therapy for Patients with Untreated, Advanced Colorectal Cancer E5202 N0147 N0543 A Randomized Phase III Study Comparing 5-FU, Leucovorin, and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin, and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers - Translational Component A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer - Translational Component A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma - Translational Component

7 Disease#Site=GI =Ancillary Site

8 Number Protocol Description Disease#Site=GU =Treatment 2805 A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patiens with Resected Renal Cell Carcinoma 3805 CTSU: CHAARTED; ChemoHormonal Therapy vs. Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone MDA-3410 A Prospective Randomized Phase III Trial Comparing Consolidation Therapy with or without Strontium-89 Following Induction Chemotherapy in Androgen-Independent Prostate Cancer S0421 Disease#Site=GU =Ancillary Phase III Study of Docetaxel and Atrasentan versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer Site

9 Number Protocol Description Disease#Site=GYN =Treatment 0218 A Phase III Trial of Carboplatin and Paclitaxil plus Placebo versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC #704865, IND #7921) followed by Placebo, versus Carboplatin and Paclitaxel Plus concurrent and Extended Bevacizumab in Women with Newly diagnosed, Previously Untreated, Suboptimal Advanced Stage Epithelial Ovarian and Primary Peritonial Cancer GOG0209 Randomized Phase III Trial of Coxorubicin/Cisplatin/Paclitaxel and G-CSF Versus Carboplatin/Paclitaxel in Patients With Stage III and IV or Recurrent Endometrial Cancer Site

10 R0522 Disease#Site=Head & Neck =Treatment A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin Versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) Followed by surgery for Selected Patients for Stage III and IV Head and Neck Carcinomas Site

11 Disease#Site=Hematology =Treatment 4402 Randomized Phase III Trial Comparing Two Different Rituximab Dosing Rgimens for Patients with Low Tumor Burden Indolent Non-Hodkin''s Lymphoma A Phase III Randomized Study of R-CHOP v. Dose-adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas E1F05 E2902 N038H N048F N0683 S0106 S0521 Phase II Study of Rituximab Given in Conjunction with Standard Chemotherapy in Primary Central Nervous System (CNS) Lymphoma A Phase III Randomized Study of Farnesyl Transferase Inhibitor R in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission after Primary Induction Failure or Patients over Age 60 in First Remission A Phase II Study of CCI-779 in Combination with Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma A Phase II Trial of AZD2171 in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia Patients A Phase II Study of Sunitinib Malate for Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg) Inducstion Therapy Versus Standard Induction With Daunomycin and Cytosine Arabinoside followed by Consolidationand Subsequent Randomization to Post_consolidation Therapy With Gemtuzumab Ozogamicin (Mylotarg) or No Additional Therapy for Patients Under Age 61 With Previously Untreated De Novo Acute Myeloid Leukemia (AML) A Randomized Trial of Maintenance versus Observation for Patients with Previously Untreated Low and Intermediate Risk Acute Promyelocytic Leukemia (APL) Disease#Site=Hematology =Ancillary Number E1F05 N038H N048F N0683 S9910 Protocol Description Phase II Study of Rituximab Given in Conjunction with Standard Chemotherapy in Primary Central Nervous System (CNS) Lymphoma - Translational Component A Phase II Study of CCI-779 in Combination with Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma A Phase II Trial of AZD2171 in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients - Translational Component A Phase II Study of Sunitinib Malate for Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - Translational Component Leukemia Centralized Reference Laboratories and Tissue Repositories Ancillary

12 Number Protocol Description Disease#Site=Hematology =Ancillary SWOG-9007 Cytogenetic Studies in Leukemia Patients Site

13 Disease#Site=Lung =Treatment 0617 A Randomized Phase III Comparison of Standard-Dose (60 Gy) Versus High-Dose Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel in Patients With Stage IIIA/B Non-Small Cell Lung Cancer E1505 N0321 N0528 N0621 N0623 N0626 A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (>= 4 cm) -IIIA Non-Small Cell Lung Cancer (NSCLC) Phase I/II Study of PS-341 in Combination with Paclitaxel, Carboplatin, and Concurrent Thoracic Radiation Therapy for Non-small Cell Lung Cancer (NSCLC) A Randomized Phase II Study of Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Advanced Non-Small Cell Lung Cancer Phase II Study of the c-src Inhibitor, AZD0530, After Four Cycles of Cytoreductive Chemotherapy for Patients With Extensive Stage Small Cell Lung Carcinoma Phase II Study of GW in Patients with Malignant Pleural Mesothelioma A Phase II Randomized Study of Pemetrexed With Sorafenib Versus Pemetrexed Alone as Second-line Therapy in Patients With Advanced Non-Small Cell Lung Cancer N0321 N0528 N0626 S0424 Disease#Site=Lung =Ancillary Phase I/II Study of PS-341 in Combination with Paclitaxel, Carboplatin, and Concurrent Thoracic Radiation Therapy for Non-small Cell Lung Cancer (NSCLC) - Translational Component A Randomized Phase II Study of Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Advanced Non-Small Cell Lung Cancer - Translational Component Immunohistochemistry (IHC) of target proteins of pemetrexed (TS, DHFR, and GARFT) Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men S9925 Lung Cancer Specimen Repository Protocol, Ancillary Study to S Site

14 Disease#Site=Melanoma =Treatment 2603 A Double-blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and BAY versus Carboplatin, Paclitaxel and Placebo in Patients with Unresectable Locally Advanced or Stage IV Melanoma N0275 N057E N0675 Phase II Trial Evaluating Resection Followed by Adjuvant Radiation Therapy (RT) for Patients with Desmoplastic Melanoma A Phase II Trial of Carboplatin (CBDCA) and ABI-007 (ABX) in Patients with Unresectable Stage IV Melanoma A Phase II Study of Temozolomide and Everolimus (RAD001) Therapy for Metastatic Melanoma Disease#Site=Melanoma =Ancillary N0377 Phase II Trial of RAD-001 in Metastatic Malignant Melanoma N057E A Phase II Trial of Carboplatin (CBDCA) and Abraxane (ABX) in Patients with Unresectable Stage IV Melanoma - Translational Component N0675 VEGF ELISA Site

15 N0392 N04C2 Disease#Site=Multiple =Ancillary Assessment of Patient Satisfaction with Participation in Phase II/III Clinical Trials An Exploratory, Randomized, Placebo-Controlled Trial of Depot Octreotide (Sandostatin LAR Depot ) for Symptomatic Ascites in Cancer Patients Site

16 E5597 N03CB N04CA N05C5 Disease#Site=Other =Ancillary Phase III Chemoprevention Trial of Selenium Supplementation in Persons With Resected Stage I Non-Small Cell Lung Cancer An Exploratory, Placebo-Controlled Trial of Prophylactic Tetracycline for Gefitinib- or Cetuximab- Induced Skin Rash (or Other Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Skin Rash) Pilocarpine for Vaginal Dryness: A Phase III Randomized, Double Blind, Placebo-Controlled Study A Phase III Randomized, Placebo-controlled, Double-blind Trial to Determine the Effectiveness of a Urea/Lactic Acid-Based Topical Keratolytic Agent and Vitamin B-6 for Prevention of Capecitabine-Induced Hand and Foot Syndrome NLTEM Long Term Event Monitoring Protocol: An Administrative Tool Site

17 Number Protocol Description Disease#Site=Unknown =Ancillary E1Y03 Master Protocol for Pharmacogenetic and Genomic Studies Site

18 Month Year North Central Cancer Treatment Group Administrative Report Case by Month For Memberships 02/01/2007 to 02/04/2008 Table 5 Treatment Cancer Control CTSU Endorsed Treatment CTSU Unendorsed Treatment CTSU Endorsed Control CTSU Unendorsed Control February March April May June July August September October November December January

19 North Central Cancer Treatment Group Administrative Report Case For Memberships or Intergroup Studies Table 6 Membership Treatment Mo. Treatment Mo. Cancel Control Mo. Cancer Control Mo. Allegheny WP Ann Arbor Arizona Atlanta Bismarck Carle Cedar Rapids Colorado CCOP Columbus Dayton Des Moines Duluth Fargo Geisinger Georgia CCOP Grand Forks Green Bay Gulf CCOP Hawaii CCOP Heartland Jacksonville Lehigh MN CGOP Mayo Metro MN Mo Valley Montana N Indiana Ochsner Oklahoma Peoria Rapid City Saskatchewan Sioux City Sioux Falls

20 North Central Cancer Treatment Group Administrative Report Case For Memberships or Intergroup Studies Table 6 Membership Treatment Mo. Treatment Mo. Cancel Control Mo. Cancer Control Mo. St. Cloud Toledo Upstate Carol Wichita

21 North Central Cancer Treatment Group Administrative Report Ancilary and Tissue Bank For Memberships or Intergroup Studies Table 7 Membership Ancilary Mo. Tissue Bank Mo. Ancilary Mo. Tissue Bank Mo. Allegheny WP Ann Arbor Arizona Atlanta Bismarck Carle Cedar Rapids Colorado CCOP Columbus Dayton Des Moines Duluth Fargo Geisinger Georgia CCOP Grand Forks Green Bay Gulf CCOP Hawaii CCOP Heartland Jacksonville Lehigh MN CGOP Mayo Metro MN Mo Valley Montana N Indiana Ochsner Oklahoma Peoria Rapid City Saskatchewan Sioux City Sioux Falls

22 North Central Cancer Treatment Group Administrative Report Ancilary and Tissue Bank For Memberships or Intergroup Studies Table 7 Membership Ancilary Mo. Tissue Bank Mo. Ancilary Mo. Tissue Bank Mo. St. Cloud Toledo Upstate Carol Wichita

23 Site/ Protocol Description North Central Cancer Treatment Group Administrative Report Current Status of Protocols Closed Within Last 12 Table 8 Ancillary N064C A Pooled Analysis of Outcomes in Younger Versus Older Patients with Metastatic Cancer of the Esophagus, Stomach, and Gastroesophageal Junction N0037 Effect of HER2 Expression by FISH and Immunohistochemistry on Response to Paclitaxel/Carboplatin Therapy in Metastatic Breast Cancer Breast B-38 A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women with Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed by DD Paclitaxel (DD AC->P); DD AC Followed by DD Paclitaxel Plus Gemcitabine (DD AC->PG) MA.20 N0338 N0437 A Phase III Study of Regional Radiation Therapy in Early Breast Cancer Phase II Trial of Docetaxel and Carboplatin Administered Every Two Weeks as Induction Therapy for Stage II or III Breast Cancer Phase II Trial of CT-2103 (Xyotax) with Capecitabine as First-Line Chemotherapy for Patients with Metastatic Breast Cancer CNS A Phase III (Phase I Closed) Randomized Study of Radiation Therapy and Temozolomide (IND #60,265) Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma and Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant) Cancer Control N01C5 N02C4 N04C7 N05C3 N05C4 N05C9 N06C4 The Use of Valeriana Officinalis (Valerian) in Improving Sleep in Patients Who Are Undergoing Treatment for Cancer: A Phase III Randomized, Placebo-Controlled, Double-Blind Study Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for Cancer-Associated Weight Loss A Phase III Randomized, Placebo-Controlled, Double Blind Study of Intravenous Calcium/Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity The Use of Vitamin E for Prevention of Chemotherapy Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study A Phase III, Randomized, Double-blind, Placebo-Controlled Trial of Prophylactic Topical Sunscreen to Prevent Erlotinib- or Cetuximab-Induced Skin Rash or Other Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Skin Rash Phase III Randomized, Double-blind, Placebo-controlled Evaluation of Citalopram for the Treatment of Hot Flashes Phase III Randomized Double-Blind Study of Mometasone Furoate versus Placebo in the Prevention of Radiation Dermatitis in Breast Cancer Patients Receiving Radiation Therapy GI N044E A Phase II Trial of Preoperative Radiation and Chemotherapy (Pemetrexed and Carboplatin) for Locally Advanced Esophageal Cancer N044J A Phase II Study of AZD2171 in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma Date Activated Date Closed 06/08/ /08/ /09/ /25/ Reason Protocol Closed 02/15/ /03/ accrual met 10/09/ /02/ accrual met 08/05/ /06/ /10/ /20/ accrual met 12/21/ /30/ /19/ /09/ accrual met 12/17/ /13/ /13/ /19/ /01/ /14/ /13/ /13/ /03/ /13/ /17/ /07/ accrual met 04/28/ /09/ /16/ /31/

24 Site/ Protocol Description North Central Cancer Treatment Group Administrative Report Current Status of Protocols Closed Within Last 12 Table 8 C-09 A Phase III Clinical Trial Comparing Oxaliplatin, Capecitabine and Hepatic Arterial Infusion of Floxuridine to Oxaliplatin and Capecitabine in Patients with Resected or Ablated Liver Metastasis from Colorectal Cancer N014A E2204 A Phase II Study of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) for Patients With Unresectable Hepatic Metastases from Metastatic Adenocarcinoma of the Colon or Rectum An Intergroup Randomized Phase II Study of Bevacizumab (NSC ) or Cetuximab (NSC ) in Combination with Gemcitabine and in Combination with Chemoradiation (Capecitabine and Radiation) in Patients with Completely-Resected Pancreatic Cancer GU 8802 A Phase II Trial of Doxorubicin and Gemcitabine in Metastatic Renal Cell Carcinoma with Sarcomatoid Features A Randomized Double-Blinded Placebo Controlled Phase III Trial Comparing Docetaxel and Prednisone with and without Bevacizumab (IND#7921, NSC#704865) in Men with Hormone Refractory Prostate Cancer GYN GOG0198 A Randomized Study of Tamoxifen versus Thalidomide in Patients with Biochemical-Recurrence- Only Epithelial Ovarian Cancer, Cancer of the Fallopian Tube, and Primary Peritoneal Carcinoma After First Line Chemotherapy Hematology N0489 Phase II Study of Epratuzumab, Rituximab (ER)-CHOP for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma E4A03 A Randomized Phase III Study of CC-5013 plus Dexamethasone versus CC-5013 plus Low Dose Dexamethasone in Multiple Myeloma with Thalidomide plus Dexamethasone Salvage Therarpy - CTSU Lung N0423 Phase II Trial of Pemetrexed Disodium and Carboplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer S0124 Randomized Phase III Trial of Cisplatin and Irinotecan (NSC ) Versus Cisplatin and Etoposide in Patients with Extensive Stage Small Cell Lung Cancer (E-SCLC) 0214 A Phase III Comparison of Prophylactic Cranial Irradiation Versus Observation in Patients with Locally Advanced Non-Small Cell Lung Cancer N0028 N0422 N0426 Phase I/II Study of Concurrent Chemotherapy and Escalating Doses 3-D Conformal Radiotherapy (RT) Followed by Three Cycles of Chemotherapy for Unresectable Non-Small Cell Lung Cancer (NSCLC) Using a New RT Paradigm Cetuximab (C225) and Radiation in Elderly and/or Poor Performance Status Patients with Locally Advanced Non-Small Cell Lung Cancer: A Phase II Study to Evaluate Survival and Toxicity A Phase II Study of Pemetrexed Disodium (ALIMTA) Plus Bevacizumab in Patients with Stage IIIB Pleural Effusion or Stage IV Non-Small Cell Lung Cancer (Second-Line Treatment) Date Activated Date Closed Reason Protocol Closed 01/18/ /12/ slow accrual 12/03/ /26/ /28/ /09/ accrual met 08/24/ /19/ /12/ /21/ accrual met 12/04/ /23/ /20/ /14/ accrual met 02/08/ /01/ /03/ /18/ ineffective 12/18/ /01/ accrual met 11/16/ /30/ slow accrual 05/17/ /04/ compet prot 01/27/ /01/ accrual met 05/19/ /23/ accrual met

25 Site/ Protocol Description S0220 E1B03 North Central Cancer Treatment Group Administrative Report Current Status of Protocols Closed Within Last 12 Table 8 A Phase II Trial of Induction Chemoradiotherapy with Cisplatin/Etoposide Followed by Surgical Resection Followed by Docetaxel for Non-Small Cell Lung Cancer Involving the Superior Sulcus (Pancoast Tumors) Pemetrexed Plus Gemcitabine or Carboplatin in Patients with Advanced Malignant Mesothelioma: A Randomized Phase II Trial Melanoma N0071 Dose Finding Study of Aerosolized GM-CSF in the Treatment of Metastatic Melanoma in the Lung Date Activated Date Closed 12/19/ /01/ /09/ /12/ Reason Protocol Closed 05/10/ /03/ drug unavail N0377 Phase II Trial of RAD-001 in Metastatic Malignant Melanoma 04/22/ /02/ ineffective Other N0691 A Meta Analysis of QOL Differences by Race in Patients on and Mayo Trials Sarcoma Z9001 A Phase III Randomized Double-Blind Study of Adjuvant STI571 (Gleevec ) Versus Placebo in Patients Following the Resection of Primary Gastrointestinal Stromal Tumor (GIST) Unknown N004E A Phase II Study of Gemcitabine (GEMZAR) and Irinotecan (CPT-11) in Previously Untreated Patients with Measurable Disease with Unknown Primary Carcinoma 08/31/ /31/ /19/ /18/ /20/ /31/ ineffective

26 Protocol North Central Cancer Treatment Group Administrative Report Intergroup Studies Where is the Monthly Case As of 02/04/08 Table 9 Randomizing Group Past 3 Past 9 Excluded N0147 ACOSOG CALGB CTSU ECOG GOG NCIC CTG NSABP RTOG SWOG N0434 CTSU NCIC CTG N04CA N N

27 North Central Cancer Treatment Group Administrative Report by Disease Site 02/01/2007 to 02/04/ Disease Site Cancer Treatment Non Treatment Breast CNS GI GU 19 0 GYN 15 0 Head & Neck 3 0 Hematology Lung Melanoma Multiple 0 35 Other

28 North Central Cancer Treatment Group Administrative Report by members to studies where is the center 01/01/2008 to 02/04/ Disease Site Patient Breast 54 CNS 5 GI 46 Hematology 6 Lung 88 Melanoma 12 Multiple 3 Other 26

Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center

Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center 717-544-3113 PROTOCOL NO STUDY TITLE PRINCIPAL INVESTIGATOR ECOG